Mersana Therapeutics Inc (NASDAQ: MRSN) closed the day trading at $3.81 up 2.42% from the previous closing price of $3.72. On the day, 1572366 shares were traded.
Ratios:
For a better understanding of MRSN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.36. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.77.
On February 29, 2024, Wedbush Upgraded its rating to Outperform which previously was Neutral and also upped its target price recommendation from $2 to $7.
Guggenheim Upgraded its Neutral to Buy on February 29, 2024, while the target price for the stock was maintained at $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 16 ’24 when Protopapas Anna sold 29,399 shares for $2.71 per share. The transaction valued at 79,671 led to the insider holds 125,153 shares of the business.
Lowinger Timothy B sold 10,409 shares of MRSN for $28,208 on Jan 16 ’24. The SVP, Chief Sci.&Tech. Officer now owns 199,329 shares after completing the transaction at $2.71 per share. On Jan 16 ’24, another insider, DeSchuytner Brian, who serves as the SVP, COO & CFO of the company, sold 9,327 shares for $2.71 each. As a result, the insider received 25,276 and left with 54,511 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 12.54 while its Price-to-Book (P/B) ratio in mrq is 12.46.
Stock Price History:
Over the past 52 weeks, MRSN has reached a high of $9.62, while it has fallen to a 52-week low of $0.80.
Shares Statistics:
A total of 120.71M shares are outstanding, with a floating share count of 91.97M. Insiders hold about 24.18% of the company’s shares, while institutions hold 71.08% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 8 analysts. On average, analysts expect EPS of -$0.18 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.21, while EPS last year was -$0.52. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.13 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.25 and -$0.87 for the fiscal current year, implying an average EPS of -$0.67. EPS for the following year is -$0.73, with 8 analysts recommending between -$0.33 and -$0.91.
Revenue Estimates
8 analysts predict $8.5M in revenue for the current quarter. It ranges from a high estimate of $12.5M to a low estimate of –$. As of the current estimate, Mersana Therapeutics Inc’s year-ago sales were $7.8M, an estimated increase of 8.90% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $8.71M, a decrease of -18.20% less than the figure of $8.90% in the same quarter last year. There is a high estimate of $12.5M for the next quarter, whereas the lowest estimate is –$.
A total of 9 analysts have provided revenue estimates for MRSN’s current fiscal year. The highest revenue estimate was $70M, while the lowest revenue estimate was –$, resulting in an average revenue estimate of $39.06M. In the same quarter a year ago, actual revenue was $36.85M, up 6.00% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $31.96M in the next fiscal year. The high estimate is $50M and the low estimate is –$. The average revenue growth estimate for next year is down -18.20% from the average revenue estimate for this year.
